Segment Information

9 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Segment Information

(11) Segment Information

The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

Human Health - includes finished dosage form generic drugs and nutraceutical products.

Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.

Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.

The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.

Nine months Ended March 31, 2018 and 2017:

	Human Health			Pharmaceutical  Ingredients		Performance Chemicals		Unallocated Corporate			Consolidated Totals
2018
Net sales	$	301,407		$	113,406	$	127,669	$	-		$	542,482
Gross profit		57,080			17,259		27,310		-			101,649
(Loss) income before income taxes		(258,172	)*		5,795		14,121		(23,142	)		(261,398	)
2017
Net sales	$	201,686		$	121,253	$	120,759	$	-		$	443,698
Gross profit		56,424			19,867		27,672		-			103,963
Income (loss) before income taxes		13,912			7,299		13,599		(20,452	)		14,358

* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.

Three months Ended March 31, 2018 and 2017:

	Human  Health			Pharmaceutical  Ingredients		Performance Chemicals		Unallocated  Corporate			Consolidated  Totals
2018
Net sales	$	91,926		$	43,201	$	50,871	$	-		$	185,998
Gross profit		9,535			7,038		11,123		-			27,696
(Loss) income before income taxes		(265,486	)*		2,987		6,699		(7,237	)		(263,037	)
2017
Net sales	$	99,816		$	43,821	$	46,491	$	-		$	190,128
Gross profit		25,300			7,255		9,764		-			42,319
Income (loss) before income taxes		5,007			3,036		5,034		(4,565	)		8,512

* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.